Pharmacoeconomic evaluation of baritinib in the treatment of adult patient with moderate to severe rheumatoid arthritis with intolerance or lack of an adequate response to treatment with one or more basic antirheumatic drugs in the Russian Federation

Abstract

In recent years, due to the widespread use of pharmacoeconomic modeling for economic and decision analysis, the variety of pharmacoeconomic models has significantly increased, which from the point of view of methodology actualizes the problem of their systematization. The first step in solving this problem is to identify the key principles of a possible classification, for which, in turn, it is necessary to highlight and describe the interaction of the attributes of pharmacoeconomic models. In this article, the authors highlighted, grouped, and described 26 attributes of pharmacoeconomic models.